FOGHORN THERAPEUTICS INC (FHTX) Stock News
NASDAQ:FHTX - Nasdaq - US3441741077 - Common Stock - Currency: USD
FHTX Latest News, Press Relases and Analysis
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and YourBio Health, a pioneer in remote blood collection technology, today announced...
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University...
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Foghorn Therapeutics (NASDAQ:FHTX) just reported results for the second quarter...
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients...
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing...
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into...
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with...
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H....
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in...
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Junaid Bajwa, M.D., has joined its London office as Senior...
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1...
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Paul Parker has joined as Managing Partner, Capital Solutions and...
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
/PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the...
A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore
/PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, and Flagship Pioneering, the bioplatform...
Foghorn Therapeutics to Participate in the BMO Oncology Summit
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn Therapeutics to Participate in the BMO Oncology Summit
Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Mirai Bio, a company pioneering the first open end-to-end platform for...
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
/PRNewswire/ -- USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to...
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer
/PRNewswire/ -- Flagship Pioneering today demonstrated further acceleration in its strategic partnership with Pfizer Inc, announcing two research programs with...
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.